Cell Tissue Technology
Cell Tissue Group is Malaysia's leading Tissue Engineering and Regenerative Medicine company, dedicated to empowering medical innovation through research, development, and advanced healthcare solutions. They focus on tissue regeneration, stem cell research, exosome research, and innovative wound care, with a mission to improve health and longevity using cutting-edge cellular technologies and tissue engineering. The company is recognized as Malaysia's first tissue engineering firm and has achieved significant milestones including being named a 'Soonicorn' with a valuation nearing US$1 billion.
Industries
Nr. of Employees
small (1-50)
Cell Tissue Technology
UPM-MTDC Technology Centre, Serdang, Malaysia
Products
Autologous bilayer tissue-engineered skin construct (MyDerm)
Autologous bilayer skin construct composed of patient-derived keratinocytes and fibroblasts embedded in a plasma-derived fibrin matrix for wound repair.
Allogenic bilayer tissue-engineered skin substitute (ALGRAFT)
Allogenic bilayer skin substitute comprising donor-derived fibroblasts and keratinocytes assembled on a plasma-based scaffold for temporary wound coverage.
MSC-derived extracellular vesicle product (exosome product)
Extracellular vesicles harvested from cultured umbilical cord-derived MSCs, produced in cGMP-compliant conditions for therapeutic use and research.
MSC-derived cell therapy product for systemic and local administration
Therapeutic product derived from cultured umbilical cord MSCs intended for administration via intravenous, intramuscular and other clinical delivery routes.
Conditioned media for topical wound application
Topical formulation composed of bioactive factors secreted by cultured fibroblasts or MSCs collected at high confluency for wound management.
Nebulizer delivery product for research/medical use
Nebulizer device intended for aerosol delivery of formulations for respiratory or investigational applications.
Autologous bilayer tissue-engineered skin construct (MyDerm)
Autologous bilayer skin construct composed of patient-derived keratinocytes and fibroblasts embedded in a plasma-derived fibrin matrix for wound repair.
Allogenic bilayer tissue-engineered skin substitute (ALGRAFT)
Allogenic bilayer skin substitute comprising donor-derived fibroblasts and keratinocytes assembled on a plasma-based scaffold for temporary wound coverage.
MSC-derived extracellular vesicle product (exosome product)
Extracellular vesicles harvested from cultured umbilical cord-derived MSCs, produced in cGMP-compliant conditions for therapeutic use and research.
MSC-derived cell therapy product for systemic and local administration
Therapeutic product derived from cultured umbilical cord MSCs intended for administration via intravenous, intramuscular and other clinical delivery routes.
Conditioned media for topical wound application
Topical formulation composed of bioactive factors secreted by cultured fibroblasts or MSCs collected at high confluency for wound management.
Nebulizer delivery product for research/medical use
Nebulizer device intended for aerosol delivery of formulations for respiratory or investigational applications.
Services
Clinical delivery and program management for stem cell, exosome/secretome and NK cell therapies, and advanced wound care services.
Clinical program focused on tissue-engineered human skin (TEHS) products and therapies for chronic and complex wounds.
In vitro testing and validation of formulations and products using human cells and skin models to assess safety and performance.
Manufacturing services for cell- and tissue-based products performed in regulated facilities.
Donor screening, tissue/sample intake, controlled cryopreservation and storage services for human tissues and primary cells.
Workshops and training programs on Good Manufacturing Practice for cell and tissue production and regulatory readiness.
Clinical delivery and program management for stem cell, exosome/secretome and NK cell therapies, and advanced wound care services.
Clinical program focused on tissue-engineered human skin (TEHS) products and therapies for chronic and complex wounds.
In vitro testing and validation of formulations and products using human cells and skin models to assess safety and performance.
Manufacturing services for cell- and tissue-based products performed in regulated facilities.
Donor screening, tissue/sample intake, controlled cryopreservation and storage services for human tissues and primary cells.
Workshops and training programs on Good Manufacturing Practice for cell and tissue production and regulatory readiness.
Expertise Areas
- Tissue engineering
- Regenerative medicine
- Mesenchymal stem cell biology
- Extracellular vesicle and secretome therapeutics
Key Technologies
- Mesenchymal stem cell culture and expansion
- Extracellular vesicle isolation and formulation
- Conditioned media (secretome) production
- Bilayer tissue-engineered skin constructs
News & Updates
Cell Tissue Group signed an MoU with Pimpinan Pusat Muhammadiyah Group to collaborate in Indonesia, aiming to benefit patients with advanced tissue technology.
Recognized as Malaysia's 'Soonicorn' worth nearly 1 billion USD by MOSTI, highlighting its potential in biotech industry.
Featured as a rising star in Malaysia's biotech industry during the launch of the Industrial Master Plan 2030.
Cell Tissue's MyDerm™ is listed among the 50 Innovation Business Opportunities by AIM, with potential revenue of RM3.07 million in 3 years.
Cell Tissue Group is recognized as Malaysia's first tissue engineering firm by the Malaysia Book of Records.
Cell Tissue Group signed an MoU with Pimpinan Pusat Muhammadiyah Group to collaborate in Indonesia, aiming to benefit patients with advanced tissue technology.
Recognized as Malaysia's 'Soonicorn' worth nearly 1 billion USD by MOSTI, highlighting its potential in biotech industry.
Featured as a rising star in Malaysia's biotech industry during the launch of the Industrial Master Plan 2030.
Cell Tissue's MyDerm™ is listed among the 50 Innovation Business Opportunities by AIM, with potential revenue of RM3.07 million in 3 years.
Cell Tissue Group is recognized as Malaysia's first tissue engineering firm by the Malaysia Book of Records.